Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (22234)	6/14/1998 10:41:00 PM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

FUGAZI, The diabetes conference is in Chicago this weekend. I just did a "leptin" search at: sc98.cjp.com and although there were 40 abstracts with leptin in their title, I didn't see one that would match the study that you described (although I didn't click on each of the 40 abstracts and didn't try other searches). However, injected leptin into humans would almost certainly be a part of the AMGN clinical trial and I'm not surprised by the result that you described. Their initial Phase I data indicated that high concentrations of injected leptin were required for modest weight reduction, and AMGN was working on ways to modify the drug to avoid adverse reactions at the site of injection, which correlated with higher doses.